Lead
Personalized neoantigen vaccines have moved from a compelling immunology idea to a clinically testable platform because patient-specific tumor mutations can now be sequenced quickly and translated into individualized vaccine constructs. This strategy is motivated by evidence that spontaneous peripheral immune recognition of tumor neoantigens is uncommon (with fewer than 1% of mutations inducing a T-cell response in tumor-bearing patients), and that current immunotherapies tend to benefit patients with higher mutation burdens, leaving many tumors immunologically “cold” without additional priming.[1] By May 2026, the strongest randomized clinical evidence for a personalized mRNA neoantigen vaccine is in resected high-risk melanoma, where adding intismeran autogene (mRNA-4157, V940) to pembrolizumab improved recurrence-free survival compared with pembrolizumab alone in a phase 2b trial.[2] In parallel, BioNTech’s autogene cevumeran (BNT122/RO7198457) program in resected pancreatic ductal adenocarcinoma (PDAC) has reported multi-year immune persistence and a marked separation in recurrence-free survival between immune “responders” and “non-responders” in early-phase data, supporting ongoing randomized testing.[3–5]
How they actually work
The core scientific premise is individualized neoantigen selection: each patient’s tumor harbors a private set of somatic mutations, and a vaccine can be designed to encode peptides derived from those mutations that are predicted to be presented by the patient’s HLA molecules. The operational workflow typically begins with obtaining tumor and matched normal tissue, sequencing them, and identifying tumor-specific variants (for example, single nucleotide variants present in tumor but not in normal tissue).[6] A computational selection step then prioritizes candidate mutations predicted to bind the patient’s HLA type, creating an individualized list of neoantigen targets.[6, 7] For mRNA-4157/V940 specifically, the product is described as a lipid-encapsulated individualized neoantigen therapy consisting of a synthetic mRNA coding for up to 34 neoantigens designed and produced based on the patient’s tumor mutational signature.[8, 9]
After injection, the encoded neoantigen sequences are translated endogenously, then processed and presented on MHC class I and MHC class II complexes, supporting coordinated activation of CD8+ cytotoxic T lymphocytes and CD4+ helper T cells.[8, 10] In this way, the vaccine aims to increase endogenous antitumor T-cell responses against patient-specific tumor mutations.[11]
A practical constraint is speed. For mRNA-4157/V940, manufacturing is reported to take about 6–7 weeks.[6] In a separate personalized mRNA neoantigen effort (mRNA-4650), the reported turnaround time for vaccine manufacture was 42–60 days.[12]
The table below summarizes key “state of the field” program elements directly supported by the provided sources.
Melanoma
The most mature randomized dataset for a personalized mRNA neoantigen vaccine is KEYNOTE-942, an open-label, randomized phase 2b adjuvant study in patients with completely resected high-risk cutaneous melanoma.[2] Patients with stage IIIB–IV melanoma were randomized 2:1 to mRNA-4157 plus pembrolizumab (n=107) versus pembrolizumab alone (n=50), with median follow-up 23 months and 24 months, respectively.[2] The regimen used intramuscular mRNA-4157 (maximum nine doses) plus intravenous pembrolizumab (maximum 18 doses) in 3-week cycles.[2]
Efficacy in this phase 2b trial was measured primarily as recurrence-free survival (RFS). RFS was longer in the combination arm than with pembrolizumab alone, with a hazard ratio for recurrence or death of 0.561 (95% CI 0.309–1.017; two-sided p=0.053), alongside a lower recurrence-or-death event rate (24/107 [22%] vs 20/50 [40%]) and an 18-month RFS of 79% versus 62%.[2] With longer follow-up (data cutoff 03 Nov 2023), the reported median follow-up was 34.9 months (range 25.1–51.0 months), and the 2.5-year RFS rates were 74.8% for the combination versus 55.6% for pembrolizumab alone.[11]
Safety and tolerability were consistent with combining a vaccine platform with checkpoint blockade. In KEYNOTE-942, most treatment-related adverse events were grade 1–2; grade ≥3 treatment-related adverse events occurred in 25% of patients on the combination versus 18% on pembrolizumab alone, with no mRNA-4157–related grade 4–5 events.[2] Immune-mediated adverse event frequency was similar in both arms (36% in each group).[2]
Mechanistic correlates are being explored to connect vaccination to clinical benefit. In an exploratory ctDNA-evaluable subgroup, baseline ctDNA-negative patients had higher RFS with mRNA-4157 (V940) plus pembrolizumab than with pembrolizumab alone (n=77 vs n=33), corresponding to an HR of 0.225 (95% CI 0.095–0.531); the same report explicitly notes that small ctDNA subgroup sizes limit interpretation.[20]
A key next step is confirmatory evidence from blinded phase 3 trials. INTerpath-001 (NCT05933577) is a global, randomized, double-blind phase 3 trial in resected high-risk stage II–IV cutaneous melanoma comparing adjuvant pembrolizumab plus V940 versus pembrolizumab plus placebo, with RFS as the primary endpoint and DMFS, overall survival, safety/tolerability, and quality of life as secondary endpoints.[13, 14] The dosing schedule specifies pembrolizumab every 6 weeks and V940/placebo every 3 weeks for up to 9 doses (or until recurrence, unacceptable toxicity, or withdrawal).[13] Media and company-facing reporting has described INTerpath-001 as fully enrolled, while other coverage has described it as enrolling, underscoring that trial-status reporting can vary across sources and timepoints.[21, 22]
Pancreatic cancer
PDAC is a high-need setting for immune priming strategies: one provided trial document notes that approximately 90% of patients die within two years of diagnosis, and that even with resection, relapse remains high with 5-year overall survival of about 20% with surgery plus adjuvant chemotherapy and about 10% without adjuvant chemotherapy.[18] Against this clinical backdrop, autogene cevumeran is being studied as an individualized mRNA neoantigen vaccine intended to induce a neoantigen-directed immune response, with IV delivery in an RNA–LPX designed to target dendritic cells and provide innate co-stimulation.[16, 17, 23]
In the investigator-initiated, single-center phase 1 PDAC trial (NCT04161755), patients received sequential anti–PD-L1 atezolizumab (a single pre-vaccination dose), followed by 8 intravenous priming doses of the individualized uridine-based mRNA neoantigen vaccine (autogene cevumeran) administered 3 weeks after atezolizumab, then standard-of-care mFOLFIRINOX (12 cycles) and a single vaccine boost.[3] The safety-evaluable cohort comprised 16 vaccinated patients (from a total of 19 patients who underwent surgery and received atezolizumab).[3, 15] In these 16 vaccinated patients, 1/16 (6%) had a vaccine-related grade 3 fever and hypertension, with no other grade ≥3 adverse events reported in the provided excerpt.[18]
Immunogenicity and outcome associations are central to how early PDAC data are being interpreted. The treatment induced de novo neoantigen-specific T-cell responses in 8/16 patients, increasing from undetectable levels to large fractions of circulating T cells (median 2.9%).[18] In an extended follow-up analysis (median follow-up 3.2 years, range 2.3–4.0 years), the eight patients with vaccine-induced high-magnitude neoantigen-specific T cells had a median RFS that was not reached.[3] In contrast, a reported non-responder group had a median RFS of 13.4 months with an HR of 0.14 (0.03–0.60) and p=0.007 in the cited update.[5] A separate 3-year follow-up update reported that 6/8 immune responders remained disease-free, while 7/8 patients without an immune response showed tumor recurrence.[24]
These findings have supported randomized testing in resected PDAC. BioNTech and Genentech describe an ongoing open-label, multicenter, randomized phase 2 trial (NCT05968326), started in October 2023, evaluating adjuvant autogene cevumeran plus atezolizumab and chemotherapy versus standard-of-care mFOLFIRINOX, with an expected enrollment of 260 patients and disease-free survival as the primary endpoint.[16, 23, 25] BioNTech also describes an on-demand iNeST manufacturing process under GMP conditions, and separate feasibility work has reported a best-case manufacturing turnaround time of 28 days from reception and approval of a complete sample set to the end of manufacturing.[4, 17]
Beyond melanoma and PDAC
The broader individualized neoantigen vaccine field includes both mRNA and non-mRNA modalities, and many mechanistic lessons have come from peptide-based vaccines combined with checkpoint blockade. In a phase Ib study of the personalized peptide neoantigen vaccine NEO-PV-01 plus nivolumab, 82 patients were enrolled and received at least one nivolumab dose, with no treatment-related serious adverse events observed.[26] Among vaccinated patients (n=60) with at least 12 months of follow-up, objective response rates were 59% in melanoma, 39% in NSCLC, and 27% in bladder cancer, and median progression-free survival was 23.5 months, 8.5 months, and 5.8 months in those cohorts, respectively.[26] The NEO-PV-01 manufacturing schema illustrates a common personalized-vaccine pipeline: tumor mutation identification by whole-exome and RNA sequencing, neoepitope selection using bioinformatics algorithms, and formulation of up to 20 long peptides mixed with poly-ICLC.[26]
Earlier melanoma studies also support the biological plausibility of personalized neoantigen vaccination. A personalized RNA-based vaccine was administered to 13 patients with stage III–IV melanoma in Sahin et al. (2017), with reports that among five patients with evident metastatic disease at vaccination, two experienced objective responses attributable to the vaccine alone.[27] In a separate personalized peptide vaccine study in resected stage III–IV melanoma (Ott et al., 2017), none of the four stage III patients recurred in the described follow-up, and the two metastatic patients who later relapsed experienced complete responses to subsequent anti–PD-1 therapy.[27]
For personalized mRNA vaccines beyond melanoma, the provided sources include public statements that Moderna and Merck announced a phase 3 trial in NSCLC using the same combination regimen framework, but they do not supply design details or results in the excerpts provided here.[22]
Regulatory status
Regulatory agencies have recognized the melanoma signal while requiring confirmatory evidence. Based on KEYNOTE-942/mRNA-4157-P201 data, the U.S. FDA granted Breakthrough Therapy Designation to mRNA-4157 (V940) in combination with pembrolizumab for adjuvant treatment of high-risk melanoma following complete resection, and the EMA granted PRIME designation for the same combination.[8, 20] A separate summary similarly situates the Breakthrough Therapy Designation in February 2023 following KEYNOTE-942 results.[28]
In parallel, pivotal-style trial designs are in place to test whether phase 2b RFS improvements translate to durable benefit and to better characterize distant metastasis-free survival and overall survival. INTerpath-001 specifies RFS as the primary endpoint, with DMFS and OS among secondary endpoints, and plans for hazard ratio estimation using stratified Cox regression with the Efron method and between-group comparisons via stratified log-rank testing.[13, 14]
Limitations and open questions
The central limitation of the current evidence base is that the most prominent efficacy signal for a personalized mRNA cancer vaccine comes from an open-label phase 2b melanoma trial, and open-label designs can introduce assessment and management differences that blinded confirmatory trials are designed to mitigate.[2, 13] Even within KEYNOTE-942, the field is still primarily working with recurrence-free endpoints rather than mature overall-survival data, while confirmatory trials explicitly track OS as a secondary endpoint over longer timeframes.[2, 14]
Manufacturing and logistics remain intrinsic constraints: producing an individualized mRNA product is reported to take 6–7 weeks for mRNA-4157/V940, and 42–60 days in an mRNA-4650 experience, creating a built-in delay that must fit within postoperative treatment windows.[6, 12] This constraint interacts with trial eligibility rules; for example, INTerpath-001 excludes patients if more than 13 weeks elapse between last resection and first pembrolizumab dose, reflecting the need to start systemic therapy within a defined postoperative interval.[14]
Biology is another limiter: in PDAC, only half of vaccinated patients in the phase 1 cohort developed de novo neoantigen-specific T-cell responses, and clinical interpretations emphasize responder–non-responder separations rather than uniform benefit across all treated patients.[18, 24] Finally, exploratory biomarker analyses (such as ctDNA-defined subgroups in melanoma) can generate testable hypotheses but may be underpowered; the provided ctDNA report explicitly warns that small subgroup sizes limit interpretation.[20]
Taken together, the May 2026 state of the science supports a cautious but evidence-based conclusion: personalized mRNA neoantigen vaccination can be manufactured on clinically relevant timelines, can induce measurable neoantigen-specific T-cell responses, and in melanoma has shown improved recurrence-free survival in randomized phase 2b testing; the key unresolved question is how consistently these immune and RFS signals will generalize across patients, tumor types, and confirmatory phase 3 trial designs.[2, 6, 13, 18]
